A prescription leaves an ingredient question — 503A
Wolverine pharmacy access under FDA 503A rules isn't settled
Pain that keeps you awake may lead you to discuss new treatments with your doctor. BPC-157 TB-500 pharmacy use remains unclear. FDA staff opposed adding both to the 503A ingredient list considered in July 2026.
Withdrawn requests haven't given pharmacies a clear answer
A stiff joint can bring you to your doctor for help. BPC-157 TB-500 access isn't established by a prescription alone. FDA placed both ingredients in Category 2, its serious-safety-risk group, under section 503A for pharmacy-made prescription medicine [13]. FDA's September 29, 2023 update showed that status.
The people or groups who asked FDA to list the ingredients later withdrew their requests. FDA's page dated April 22, 2026 puts those requests with withdrawn entries instead of Category 2 [13][14]. That changes where the ingredients appear on the page; it doesn't declare them safe or approved. The account doesn't explain why the requests were withdrawn or whether a 503A pharmacy may now use either ingredient.
An advisory committee then considered both for the 503A list in July 2026. Neither BPC-157 nor TB-500 is an FDA-approved medicine [13]. The blend also lacks approval for treating your injury. I'd want the ingredient question answered before treating your prescription as proof of lawful access.
Here's what that uncertainty means when you visit a pharmacy. The committee advises FDA; FDA makes the final ingredient-list decision. Discussing the ingredients didn't give a pharmacy new permission. You still lack a published answer settling your access after withdrawal.
The July 23-24, 2026 meeting gave no final access decision
The forward-leaning part of this page rests on a single dated, FDA-citable fact: the FDA Pharmacy Compounding Advisory Committee (PCAC) met on July 23-24, 2026, to discuss bulk drug substances being considered for inclusion on the 503A bulks list [15]. Both of the Wolverine blend's constituents were on that agenda.
BPC-157 (listed as "BPC-157 (free base)" / "BPC-157 acetate") appeared on the published agenda as a substance being considered for inclusion on the 503A bulks list [13][15]. TB-500 (listed as "TB-500 (free base)" / "TB-500 acetate," the LKKTETQ fragment FDA associates with thymosin beta-4) appeared on the same agenda, in the same capacity [13][15]. The two components remain aligned: their nominations were withdrawn, FDA staff proposed against listing each one, and no FDA record of the committee's votes had appeared as of September 2026.
What this meeting was, and was not, has to be stated carefully. Inclusion on a final 503A bulks list is decided by FDA rulemaking informed by the committee; being discussed by the committee is a step in evaluation, not a final listing decision [14]. The meeting opened no door by itself — FDA staff had argued against listing either peptide, and no new status for them has been published, dated or confirmed since. Anyone reading a vendor claim that these peptides were "moved back" or "removed" on a specific 2026 date should treat it as unconfirmed: FDA's page gives no date for any change, and the July 2026 meeting that took both up as candidates has left no published vote record, which reads as an evaluation still unfinished rather than resolved [15].
Clinical care runs on its own track. Under Promise Peptides (mypromise.com), prescription peptide care starts with a licensed clinician's evaluation, after which Wolverine (research blend) may be prescribed; none of that settles the committee questions above.
Your health review and the pharmacy ingredient rule both matter
Your doctor first needs to decide whether specially made medicine fits your health. Two parts of U.S. law govern how your medicine is made [14]. Section 503A covers licensed pharmacies, federal facilities, and doctors usually making medicine for a named patient with a prescription. Section 503B covers FDA-registered facilities making bigger batches under stricter production checks.
The usual steps for specially made medicine start with your examination [16]. A prescriber weighs your condition and health history. A prescription then leaves the pharmacy's ingredient duties to be met. All those steps matter for lawful care.
- A licensed prescriber examines you in person or through a lawful remote visit. Your health needs guide the decision. The prescriber decides whether specially made medicine is suitable.
- If suitable and lawful, the prescriber writes a prescription naming you. Your own health remains the reason for the prescription. That document doesn't permit every ingredient a pharmacy might use.
- A licensed 503A pharmacy supplies medicine for an individual patient. An FDA-registered 503B facility can supply larger batches or office stock. Either supplier still has legal duties concerning the ingredients.
Your prescriber can also examine you during a lawful remote visit [16]. The examination and prescription still have to meet the law. Meeting remotely doesn't change which ingredients your pharmacy may use. It doesn't resolve FDA's unanswered question about this pair.
Your pharmacy needs one of three legal grounds for each ingredient [14]. The ingredient can meet the official drug standard accepted by U.S. law, which sets the required contents and purity. Or the ingredient must be part of an FDA-approved drug or appear on FDA's allowed-ingredient list for that kind of pharmacy.
While an ingredient stays in FDA's serious-risk group, routine 503A use isn't allowed. BPC-157 and TB-500 were flagged in 2023 [13][16]. Their requests were later withdrawn, without a clear FDA answer about whether pharmacy use is now permitted.
Drug approval hasn't followed the withdrawn requests
Neither BPC-157 nor TB-500 has FDA drug approval. Both appeared in 503A Category 2 in FDA's September 29, 2023 update [13]. FDA's page current as of April 22, 2026 lists withdrawn requests while keeping the safety concerns. The July 23-24, 2026 meeting considered both for the 503A list, but staff opposed adding them and no published vote settles access [15].
BPC-157's withdrawn entry doesn't establish pharmacy permission
On FDA's page dated April 22, 2026, BPC-157 appears with withdrawn requests rather than in Category 2 [13][14]. That's a changed listing, without an explanation of which pharmacy rules now apply. Your prescriber must examine you, write a prescription for you, and use an ingredient your pharmacy is legally allowed to supply [16]. FDA hasn't said whether BPC-157 meets that last requirement after withdrawal.
FDA 503A safety concerns remain despite a changed listing
Both ingredients appeared in 503A Category 2 in the September 29, 2023 update [13]. FDA's page dated April 22, 2026 lists withdrawn requests outside Category 2. For an ingredient still in Category 2, FDA may stop a pharmacy supplying the ingredient or impose a penalty; the withdrawn entries don't explain the rules now applying to this pair [14]. BPC-157 and TB-500 were considered for the 503A list on July 23-24, 2026, with no published outcome by September 2026 [15].
